• Journals Master List
  • DOAJ
  • 数据库logo
  • EuroPub
LUO Man-yu, LIU Li-hua, LIU Sheng-mao, ZHANG Dong-mei. A controlled clinical study of efficacy of different treatment regimens for idiopathic membranous nephropathy[J]. Journal of Clinical Nephrology, 2019, 19(11): 798-802. DOI: 10.3969/j.issn.1671-2390.2019.11.002
Citation: LUO Man-yu, LIU Li-hua, LIU Sheng-mao, ZHANG Dong-mei. A controlled clinical study of efficacy of different treatment regimens for idiopathic membranous nephropathy[J]. Journal of Clinical Nephrology, 2019, 19(11): 798-802. DOI: 10.3969/j.issn.1671-2390.2019.11.002
shu

A controlled clinical study of efficacy of different treatment regimens for idiopathic membranous nephropathy

  • Department of Nephropathy, the Second Hospital of Jilin University, Changchun 130041, China

More Information
  • Received Date: May 05, 2019
  • Available Online: May 11, 2023
  • Published Date: November 27, 2019
    Graphical Abstract
    • Abstract
  • Objective To evaluate the clinical efficacy and safety of the following different treatment regimens for idiopathic membranous nephropathy(IMN):modified Ponticelli regimen (MPR, alternating therapy of hormone (Prednisone,Pre) combined with Cyclophosphamide (CTX), prednisone combined with CTX (Pre/CTX) and prednisone combined with Tacrolimus (Pre/TAC). Methods A total of 67 patients diagnosed with IMN by kidney biopsy from the 2nd Hospital of Jilin University were analyzed on their clinical information about urine protein and albumin. Based on the treatment regimens, they were divided into MPR group, Pre/CTX group and Pre/TAC group. All the patients were treated for 6 months. We observed clinical efficacy in the three groups for 3-month and 6-month treatment, and monitored adverse reactions during the treatment course. Results No significant difference was observed at baseline before treatment. After 3-month treatments, in the MPR group, 8 (34.7%) of 23 patients reached partly remission and the effectiveness rate is 34.7%; in the Pre/CTX group, 1 (4.2%) of 24 patients died, 1 (4.2%) reached complete remission, 8 (33.3%) reached partly remission and the effectiveness rate is 37.5%; and in the Pre/TAC group, 8 (40.0%) of 20 Pre/TAC group patients reached partly remission and the effective rate is 40.0%. The above results in the three groups have no statistical difference. After 6-months treatments, in the MPR group, 1 (4.3%) of 23 patients died, 1 (4.3%) of the rest 22 patients reached complete remission, 12 (52.2%) reached partly remission and the effectiveness rate is 56.5%; in the Pre/CTX group, 2 (8.7%) of the rest 23 patients reached complete remission, 17 (73.9%) reached partly remission and the effective rate is 82.6%; and in the Pre/TAC group, 1 of 20 patients (5.0%) reached complete remission, 12 (60.0%) reached partly remission and the effective rate is 65.0%. The results in the 3 groups have no statistical difference. MPR had less adverse reactions during the treatments. Conclusions MPR, Pre/CTX and Pre/TAC regimens have comparable effectiveness for IMN; the MPR regimen is characterized by short treatment course and less prednisone accumulation dose, and so may have a high level of safety.
    • FullText(HTML)
    • References (12)
  • [1]
    Haas M, Meehan SM, Karrison TG, et al. Changing etiologies of unexplained adult nephrotic syndrome:a comparison of renal biopsy findings from 1976-1979 and 1995-1997[J]. Am J Kidney Dis, 1997, 30(5):621-631.
    [2]
    Hogan J, Mohan P, Appel GB. Diagnostic tests and treatment options in glomerular disease:2014 update[J]. Am J Kidney Dis, 2014, 63(4):656-666.
    [3]
    Ponticelli C, Zucchelli P, Imbasciati E, et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy[J]. N Engl J Med, 1984, 310(15):946-950.
    [4]
    Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy[J]. J Am Soc Nephrol, 1998, 9(3):444-450.
    [5]
    Qin HZ, Liu L, Liang SS, et al. Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients[J]. BMC Nephrol, 2017, 18(1):2.
    [6]
    Peng L, Wei SY, Li LT, et al. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy[J].J Formos Med Assoc, 2016, 115(1):11-18.
    [7]
    Ramachandran R, Hn HK, Kumar V, et al. Tacrolimus combined with corticosteroids versus modified ponticelli regimen in treatment of idiopathic membranous nephropathy:randomized control trial[J]. Nephrology(Carlton), 2016, 21(2):139-146.
    [8]
    He L, Peng Y, Liu H, et al. Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids[J]. J Nephrol, 2013, 26(3):564-571.
    [9]
    Li Y, Liu FY, Liu ZH, et al. Effect of tacrolimus and cyclosporine a on suppression of albumin secretion induced by inflammatory cytokines in cultured human hepatocytes[J].Inflamm Res, 2006, 55(5):216-220.
    [10]
    Ramachandran R, Jairam A, Bhansali A, et al. Study of hypothalamic pituitary adrenal axis in patients of membranous nephropathy receiving modified ponticelli regimen[J]. Indian J Nephrol, 2015, 25(1):12-15.
    [11]
    Cui W, Lu X, Min X, et al. Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy[J]. Braz J Med Biol Res, 2017, 50(4):e5976.
    [12]
    毛文丽, 杜琳娜, 张真真, 等. 他克莫司或环磷酰胺联合糖皮质激素治疗特发性膜性肾病的疗效比较[J]. 临床肾脏病杂志, 2018, 18(12):756-760.
    • Related Articles

  • Related Articles

    [1]Xing Yi-xi, Chen Wei-fei, Liang Jin, Lin Qian-qi. Efficacy of tacrolimus plus glucocorticoid for lupus nephritis: a Meta-analysis[J]. Journal of Clinical Nephrology, 2024, 24(9): 728-736. DOI: 10.3969/j.issn.1671-2390.2024.09.004
    [2]Li Jin, Han Hui-shu, Wang Shu-long, Bao Yan, Peng Yi-qun. Risk factors of new-onset glucose abnormalities in idiopathic membranous nephropathy patients on glucocorticoid plus tacrolimus[J]. Journal of Clinical Nephrology, 2023, 23(11): 897-902. DOI: 10.3969/j.issn.1671-2390.2023.11.003
    [3]Zhang Cheng-ning, Duan Su-yan, Yuan Yang-gang, Zhu Jing-feng, Huang Zhi-min, Sun Bin, Zhang Bo, Mao Hui-juan, Xing Chang-ying. Analyses of factors affecting and predicting the efficacy of tacrolimus in patients with idiopathic membranous nephropathy[J]. Journal of Clinical Nephrology, 2022, 22(10): 807-813. DOI: 10.3969/j.issn.1671-2390.2022.10.003
    [4]Xiong Lian-lian, Yi Bin. Effect of genetic polymorphism on individualized treatment of tacrolimus in patients with primary nephrotic syndrome[J]. Journal of Clinical Nephrology, 2021, 21(5): 416-420. DOI: 10.3969/j.issn.1671-2390.y20-068
    [5]YANG Shuang, WANG Li-ning. Progress in pharmacogenetic studies on effect on tacrolimus concentrations[J]. Journal of Clinical Nephrology, 2020, 20(9): 752-757. DOI: 10.3969/j.issn.1671-2390.2020.09.013
    [6]CHEN Cai-ming, LI Yi-xia, LIN Jia-qun, WAN Jian-xin. Tacrolimus repairs glomerular podocytes injury in rats with adriamycin induced nephropathy[J]. Journal of Clinical Nephrology, 2020, 20(5): 405-409. DOI: 10.3969/j.issn.1671-2390.2020.05.011
    [7]LI Xiao-yong. Clinical observation of responses to two plasma concentrations of tacrolimus in treatment of idiopathic membranous nephropathy stageⅡ[J]. Journal of Clinical Nephrology, 2019, 19(8): 594-597. DOI: 10.3969/j.issn.1671-2390.2019.08.008
    [8]LIU Chun-ling, WANG Shu-qiang, GENG Xiao-dong, GUO Man-di, HONG Quan, WU Di. A retrospective study of rituximab or Tacrolimus combined with glucocorticoid for idiopathic membranous nephropathy[J]. Journal of Clinical Nephrology, 2019, 19(6): 421-425. DOI: 10.3969/j.issn.1671-2390.2019.06.008
    [9]MAO Wen-li, DU Lin-na, ZHANG Zhen-zhen, LV Chen-xiao, CUI Mei-yu. Efficacy of tacrolimus or cyclophosphamide combined with glucocorticoids in the treatment of idiopathic membranous nephropathy[J]. Journal of Clinical Nephrology, 2018, 18(12): 756-760. DOI: 10.3969/j.issn.1671-2390.2018.12.008
    [10]LIU Hui-bin, WU Han, WANG Xiao-qin. Meta-analysis of tacrolimus combined with hormone therapy for IgA nephropathy[J]. Journal of Clinical Nephrology, 2017, 17(6): 329-335. DOI: 10.3969/j.issn.1671-2390.2017.06.002

  • Cited by

    Periodical cited type(9)

    1. 高真真，王秀莲，耿明亮，段海玲. 他克莫司联合糖皮质激素治疗特发性膜性肾病的疗效及对血清指标与肾功能的影响. 中国实用医药. 2024(19): 116-119 .
    2. 张同静，康阳阳，李艳宾. 他克莫司联合糖皮质激素治疗特发性膜性肾病的效果及其对肾功能的影响. 临床医学. 2023(12): 98-100 .
    3. 姚春颖，马秋波，施莹. 环磷酰胺与他克莫司治疗特发性膜性肾病的临床效果比较. 中国当代医药. 2022(36): 57-61 .
    4. 岑雅伶，杨佳青，张丽娥，甘瑞静，杨洁，黎海娟，王明军. 原发性膜性肾病复发的多因素分析. 实用医学杂志. 2021(06): 773-777 .
    5. 熊智慧，黄新艳. 小剂量他克莫司联合雷公藤多苷多靶点辅助治疗特发性膜性肾病的临床疗效和安全性. 临床合理用药杂志. 2020(25): 80-81 .
    6. 郭宁，王娜，吕国庆. 特发性膜性肾病磷脂酶A2受体抗原表达情况与临床特征、预后的关系. 中国医师杂志. 2020(07): 1026-1029 .
    7. 朱爱民，陈秋香，米侠，张策，张驰，周飞红，王军升. 他克莫司联合中等剂量糖皮质激素治疗特发性膜性肾病的临床分析. 中外医疗. 2020(32): 115-117+167 .
    8. 丁华平，刘利芬，张定芳. 环孢霉素联合小剂量糖皮质激素治疗特发性膜性肾病的有效性及安全性分析. 药品评价. 2020(20): 38-40 .
    9. 张琳琪，蔡岩岩. 中药联合不同免疫抑制剂治疗特发性膜性肾病临床疗效观察. 中华中医药杂志. 2020(12): 6429-6433 .

    Other cited types(3)

Catalog

    Get Citation
    PDF
    XML
    Article views (338) PDF downloads (495) Cited by(12)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles
    Links

    Website Copyright © Wuhan Medical and Health Association Joint Office Editorial Department of Journal of Clinical Nephrology   备案号：鄂ICP备13011742号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return